LianBio SEC filings LIANY
LianBio has 170 filings in SEC EDGAR's recent list, going back to Nov 12, 2020. Its latest annual report, Form 10-K, was filed on Mar 28, 2023 for the period ended Dec 31, 2022. The latest quarterly report (Form 10-Q) was filed on Nov 13, 2023, covering the quarter ended Sep 30, 2023. The most recent current report (Form 8-K) was filed on Feb 13, 2024 (exit or restructuring costs, listing notice, regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Listing notice, Regulation FD disclosure, Other events
|
Feb 13, 2024 | Feb 9, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Dec 26, 2023 | Dec 22, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 20, 2023 | Dec 19, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 19, 2023 | Dec 16, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 6, 2023 | Dec 6, 2023 |
| 8-K |
Current report
Other events
|
Dec 1, 2023 | Nov 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| 8-K |
Current report
Material agreement, Agreement ended, Acquisition or sale of assets, Regulation FD disclosure
|
Oct 30, 2023 | Oct 24, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2023 | Jun 21, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 1, 2023 | May 1, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 26, 2023 | Apr 26, 2023 |
| 8-K |
Current report
Other events
|
Apr 21, 2023 | Apr 21, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 17, 2023 | Mar 14, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 19, 2022 | Dec 16, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 13, 2022 | Dec 9, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Other events
|
Oct 12, 2022 | Oct 12, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 8, 2022 | Apr 6, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2022 | Mar 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 2, 2022 | Mar 2, 2022 |
| 8-K |
Current report
Results of operations
|
Dec 9, 2021 | Dec 9, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Nov 10, 2021 | Nov 4, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 3, 2021 | Nov 3, 2021 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIANY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Princeton, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1831283
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.